The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.
Diabetes
GLP-1RA
Lungs
Pulmonary function
SGLT-2i
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
14
05
2024
accepted:
03
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
aheadofprint
Résumé
Type 2 Diabetes (T2D) is a chronic disease with increasing incidence and prevalence and serious chronic complications, especially from cardiovascular system. However, other organs can be affected too. Several studies have associated T2D, especially when poorly controlled, with multiple pulmonary diseases. T2D is a common comorbidity among patients with asthma, Chronic Obstructive Pulmonary Disease (COPD), and Obstructive Sleep Apnea Syndrome (OSAS), and it is related to higher respiratory infection incidence, prevalence and severity. Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are novel antihyperglycaemic agents with established cardiovascular benefits. There are also limited studies indicating their potential benefit in respiratory function. The aim of this article is to review data on the impact of GLP-1RA and SGLT-2i on respiratory function and describe the possible clinical benefits. Key findings indicate that GLP-1RA significantly improve lung function in patients with COPD, evidenced by improvements in spirometry measurements. Additionally, both GLP-1RA and SGLT-2i are associated with a decreased risk of severe and moderate exacerbations in COPD patients and have shown potential in reducing the incidence of respiratory disorders, including asthma and pneumonia. The mechanisms underlying these benefits are not yet fully understood and include multiple effects, such as anti-inflammatory action and oxidative stress reduction.
Identifiants
pubmed: 39289244
doi: 10.1007/s12020-024-04033-6
pii: 10.1007/s12020-024-04033-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
American Diabetes Association. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl 1):S20–S42. https://doi.org/10.2337/dc24-S002
K.L. Ong, L.K. Stafford, S.A. McLaughlin, E.J. Boyko, S.E. Vollset, A.E. Smith et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203–234 (2023)
doi: 10.1016/S0140-6736(23)01301-6
M.J. Fowler. Microvascular and macrovascular complications of diabetes [Internet]. Clin. Diabetes•. 2008. Available from: http://clinical.diabetesjournals.org
M.R. Schuyler, D.E. Niewoehner, S.R. Inkley, R. Kohn. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev. Respir. Dis. 113, 37-41 (1976).
S.A. Paschou, E. Bletsa, K. Saltiki, P. Kazakou, K. Kantreva, P. Katsaounou. et al. Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes. Nutrients. 14, 4989 (2022)
S.F. Ehrlich, C.P. Quesenberry, S.K. Van Den Eeden, J. Shan, A. Ferrara, Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 33, 55–60 (2010)
doi: 10.2337/dc09-0880
pubmed: 19808918
T. Enomoto, J. Usuki, A. Azuma, T. Nakagawa, S. Kudoh, Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 123, 2007–2011 (2003)
doi: 10.1378/chest.123.6.2007
pubmed: 12796182
Wang D., Ma Y., Tong X., Zhang Y., Fan H. Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis. Front. Public Health. 8, 196 (20200).
C. Hyldgaard, O. Hilberg, E. Bendstrup, How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 108, 647–653 (2014)
doi: 10.1016/j.rmed.2014.01.008
pubmed: 24529739
J.B. Kornum, R.W. Thomsen, A. Riis, H.H. Lervang, H.C. Schønheyder, H.T. Sørensen, Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care 31, 1541–1545 (2008)
doi: 10.2337/dc08-0138
pubmed: 18487479
pmcid: 2494631
A. Al-Sayyar, K.D. Hulme, R. Thibaut, J. Bayry, F.J. Sheedy, K.R. Short. et al. Respiratory tract infections in diabetes – lessons from tuberculosis and influenza to guide understanding of COVID-19 severity. Front. Endocrinol. 13, 91923 (2022).
S.J. McGurnaghan, A. Weir, J. Bishop, S. Kennedy, L.A.K. Blackbourn, D.A. McAllister et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82–93 (2021)
doi: 10.1016/S2213-8587(20)30405-8
pubmed: 33357491
H. Zheng, J. Wu, Z. Jin, L.J. Yan. Potential biochemical mechanisms of lung injury in diabetes. Aging Dis. 8, 7 (2017).
S. Singh, Y.S. Prakash, A. Linneberg, A. Agrawal, Insulin and the lung: connecting asthma and metabolic syndrome. J. Allergy 2013, 1–8 (2013)
doi: 10.1155/2013/627384
L. Zhang, f. Jiang, Y. Xie, Y. Mo, X. Zhang, C. Liu. Diabetic endothelial microangiopathy and pulmonary dysfunction. Front. Endocrinol. 14, 1073878 (2023).
L. Fuso, D. Pitocco, A. Longobardi, F. Zaccardi, C. Contu, C. Pozzuto et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 28, 370–375 (2012)
doi: 10.1002/dmrr.2284
pubmed: 22271438
S.A. Meo. Significance of spirometry in diabetic patients. Int. J. Diabetes Mellit. 2, 47–50 (2010).
A. Aparna. Pulmonary function tests in type 2 diabetics and non-diabetic people - A comparative study. J. Clin. Diagnos. Res. 7, 1606–1608 (2013)
S. Mittal, M. Mittal, M. Jindal, S. Srivastava, S. Sinha. Evaluation of pulmonary functions in patients with type 2 diabetes mellitus: a cross-sectional study. Cureus 15, 3–4 (2023).
O.L. Klein, J.A. Krishnan, S. Glick, L.J. Smith. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabetic Med. 27, 977–987 (2010).
W. Jiao. 1 AIC, LMG-MMER, LX. Causal associations of sleep apnea and snoring with type 2 diabetes and glycemic traits and the role of BMI. Obesity. 31, 652−664 (2023)
S. Momtazmanesh, S.S. Moghaddam, S.-H. Ghamari, E.M. Rad, N. Rezaei, P. Shobeiri et al. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine [Internet] 59, 101936 (2023). https://linkinghub.elsevier.com/retrieve/pii/S258953702300113X
doi: 10.1016/j.eclinm.2023.101936
N. Salam, M. Jevtic, S. Safiri, M. Abdollahi. Global burden of lower respiratory infections during the last three decades [Internet]. Available from: https://vizhub.healthdata.org/gbd-compare/
R. Nevola, R. Epifani, S. Imbriani, G. Tortorella, C. Aprea, R. Galiero et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int. J. Mol. Sci. 24, 1703 (2023)
E.D. Michos, G.L. Bakris, H.W. Rodbard, K.R. Tuttle. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am. J. Prev. Cardiol. 14, 10052 (2023)
M. Grieco, A. Giorgi, M.C. Gentile, M. d’Erme, S. Morano, B. Maras et al. Glucagon-Like Peptide-1: a focus on neurodegenerative diseases. Front. Neurosci. 13, 1112 (2019)
H. Yaribeygi, M. Maleki, T. Jamialahmadi, S.A. Moallem, A. Sahebkar. Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI J. 22, 403–414 (2023)
A. Pawlos, M. Broncel, E. Woźniak, P. Gorzelak-Pabiś. Neuroprotective effect of SGLT2 inhibitors. Molecules. 23, 7213 2021.
J. Nespoux, V. Vallon. Renal effects of SGLT2 inhibitors: an update. Curr. Opin. Nephrol. Hypertens. 29, 190–198 (2020)
W. Widiarti, A.C. Sukmajaya, D. Nugraha, F.F. Alkaff. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. 15, 837–843 (2021)
C. de Graaf, D. Donnelly, D. Wootten, J. Lau, P.M. Sexton, L.J. Miller et al. Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol. Rev 68, 954–1013 (2016)
doi: 10.1124/pr.115.011395
pubmed: 27630114
pmcid: 5050443
M. Körner, M. Stöckli, B. Waser, J.C. Reubi, GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nuclear Med. 48, 736–743 (2007)
doi: 10.2967/jnumed.106.038679
C.O. Mendivil, H. Koziel, J.D. Brain. Metabolic hormones, apolipoproteins, adipokines, and cytokines in the alveolar lining fluid of healthy adults: compartmentalization and physiological correlates. PLoS ONE. 10, e0123344 (2015)
D.V. Nguyen, A. Linderholm, A. Haczku, N. Kenyon. Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma. Pharmacol. Ther.180, 139–143 (2017).
A.D. Altintas Dogan, O. Hilberg, S. Hess, T.T. Jensen, E.M. Bladbjerg, C.B. Juhl, Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int. J. COPD 17, 405–414 (2022)
doi: 10.2147/COPD.S350133
R. Pradhan, S. Lu, H. Yin, O.H.Y. Yu, P. Ernst, S. Suissa et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: Population based cohort study. BMJ 379, 8–10 (2022)
Y. Albogami, K. Cusi, M.J. Daniels, Y.J.J. Wei, A.G. Winterstein, Glucagon-like peptide 1 receptor agonists and chronic lower respiratory disease exacerbations among patients with type 2 diabetes. Diabetes Care 44, 1344–1352 (2021)
doi: 10.2337/dc20-1794
pubmed: 33875487
pmcid: 8247488
P. Rogliani, M.G. Matera, L. Calzetta, N.A. Hanania, C. Page, I. Rossi et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir. Med. 154, 86–92 (2019)
doi: 10.1016/j.rmed.2019.06.015
pubmed: 31228775
J.P. Wei, C.L. Yang, W.H. Leng, L.L. Ding, G.H. Zhao, Use of GLP1RAs and occurrence of respiratory disorders: a meta-analysis of large randomized trials of GLP1RAs. Clin. Respir. J. 15, 847–850 (2021)
doi: 10.1111/crj.13372
pubmed: 33825329
M. Yu, R. Wang, L. Pei, X. Zhang, J. Wei, Y. Wen et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr. 15, 164 (2023).
A. Chaudhuri, H. Ghanim, M. Vora, C.L. Sia, K. Korzeniewski, S. Dhindsa et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198–207 (2012)
doi: 10.1210/jc.2011-1508
pubmed: 22013105
G. Bendotti, L. Montefusco, M.E. Lunati, V. Usuelli, I. Pastore, E. Lazzaroni et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol. Res. 182, 106320 (2022)
doi: 10.1016/j.phrs.2022.106320
pubmed: 35738455
W. Zhou, W. Shao, Y. Zhang, D. Liu, M. Liu, T. Jin, Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab. 319, E568–E578 (2020)
doi: 10.1152/ajpendo.00292.2020
pubmed: 32723174
pmcid: 7839242
P.D. Mitchell, B.M. Salter, J.P. Oliveria, A. El-Gammal, D. Tworek, S.G. Smith et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin. Exp. Allergy 47, 331–338 (2017)
doi: 10.1111/cea.12860
pubmed: 27928844
T. Zhu, X.L. Wu, W. Zhang, M. Xiao, Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int. J. Mol. Sci. 16, 20195–20211 (2015)
doi: 10.3390/ijms160920195
pubmed: 26343632
pmcid: 4613197
S. Gou, T. Zhu, W. Wang, M. Xiao, X.C. Wang, Z.H. Chen, Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-κB in mice. Int. Immunopharmacol. 22, 498–504 (2014)
doi: 10.1016/j.intimp.2014.07.010
pubmed: 25111852
B. Baer, N.D. Putz, K. Riedmann, S. Gonski, J. Lin, L.B. Ware et al. Liraglutide pretreatment attenuates sepsis-induced acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol 325, L368–L384 (2023)
doi: 10.1152/ajplung.00041.2023
pubmed: 37489855
pmcid: 10639010
W. Yue, F. Dang, X. Zang, Y. Du, X. Fan, H. Su, T. Pan. Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol. 949, 175730 (2023)
E. Vara, J. Arias-Díaz, C. Garcia, L. Balibrea, E. Blázquez. Glucagon-like Peptide-1(7-36) Amide Stimulates Surfactant Secretion in Human Type II Pneumocytes [Internet]. Am. J. Respir. Crit. Care. Med. (2001). Available from: www.atsjournals.org
H.P. Haagsman, R.V. Diemel. Surfactant-associated proteins: functions and structural variation. Compar. Biochem. Physiol. Part A. 129, 91−108 (2001)
J. Fandiño, L. Toba, L.C. González-Matías, Y. Diz-Chaves, F. Mallo. GLP-1 receptor agonist ameliorates experimental lung fibrosis. Sci. Rep. 10, 18091 (2020)
T. Zhu, Li C., X. Zhang, C. Ye, S. Tang, W. Zhang et al. GLP-1 analogue liraglutide enhances SP-A expression in LPS-induced acute lung injury through the TTF-1 signaling pathway. Mediat. Inflamm. 2018, 3601454 (2018)
C. López-Cano, A. Ciudin, E. Sánchez, F.J. Tinahones, F. Barbé, M. Dalmases et al. Liraglutide improves forced vital capacity in individuals with Type 2 diabetes: data from the randomized crossover LIRALUNG Study. Diabetes. 71, 315–320 (2022)
doi: 10.2337/db21-0688
pubmed: 34737187
N.E. Viby, M.S. Isidor, K.B. Buggeskov, S.S. Poulsen, J.B. Hansen, H. Kissow, Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 154, 4503–4511 (2013)
doi: 10.1210/en.2013-1666
pubmed: 24092637
P. Rogliani, L. Calzetta, B. Capuani, F. Facciolo, M. Cazzola, D. Lauro et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 55, 804–814 (2016)
doi: 10.1165/rcmb.2015-0311OC
pubmed: 27447052
T., Sato, T. Shimizu, H. Fujita, Y. Imai, D.J. Drucker, Y. Seino et al. GLP-1 receptor signaling differentially modifies the outcomes of sterile vs viral pulmonary inflammation in male mice. Endocrinology. 161, bqaa201 (2020)
Dixon A.E., Peters U. The effect of obesity on lung function. Expert. Rev. Respir. Med. Taylor and Francis Ltd.; 2018. 755–767
W. Jiang, W. Li, J. Cheng, W. Li, F. Cheng, Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breathing 27, 1687–1694 (2023)
doi: 10.1007/s11325-022-02768-y
pubmed: 36542275
Cliona O’Donnell SCAOBOMTRGKMMLDODJMJDDSR. Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study
J.I. Fonseca-Correa, R. Correa-Rotter. Sodium-Glucose Cotransporter 2 inhibitors mechanisms of action: a review. Front. Med. 8, 777861 (2021)
N.A. Elsayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer et al. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 46, S140–S157 (2023)
doi: 10.2337/dc23-S009
pubmed: 36507650
M. Qiu, L.L. Ding, Z.L. Zhan, S.Y. Liu, Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine. 73, 31–36 (2021)
doi: 10.1007/s12020-021-02644-x
pubmed: 33559806
D.G. Yin, M. Qiu, X.Y. Duan. Association between SGLT2is and cardiovascular and respiratory diseases: a meta-analysis of large trials. Front. Pharmacol. 12, 724405 (2021)
P.C.M. Au, K.C.B. Tan, D.C.L. Lam, B.M.Y. Cheung, I.C.K. Wong, W.C. Kwok et al. Association of sodium-glucose cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 inhibitor use with risk of incident obstructive airway disease and exacerbation events among patients with type 2 Diabetes in Hong Kong. JAMA Netw. Open 6, e2251177 (2023)
doi: 10.1001/jamanetworkopen.2022.51177
pubmed: 36648944
pmcid: 9857182
H.E. Jeong, S. Park, Y. Noh, S. Bea, K.B. Filion, O.H.Y. Yu et al. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study. BMC Med. 21, 47 (2023)
K. Sawada, S. Karashima, M. Kometani, R. Oka, Y. Takeda, T. Sawamura et al. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. Endocr. J. 65, 461−467 (2018)
L. Xie, S. Li, X. Yu, Q. Wei, F. Yu, J. Tong. DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - A 3-month,multicenter, randomized controlled clinical trial. Eur. J. Clin. Pharmacol. 80, 771–780 (2024)
doi: 10.1007/s00228-024-03643-3
pubmed: 38386021
M.N. Kosiborod, R. Esterline, R.H.M. Furtado, J. Oscarsson, S.B. Gasparyan, G.G. Koch et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 9, 586–594 (2021)
doi: 10.1016/S2213-8587(21)00180-7
pubmed: 34302745
pmcid: 8294807
F. Lin, C. Song, Y. Zeng, Y. Li, H. Li, B. Liu et al. Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization. Int. Immunopharmacol. 88, 106969 (2020)
E.E. Abd El-Fattah, S. Saber, A.A.E. Mourad, E. El-Ahwany, N.A. Amin, S. Cavalu et al. The dynamic interplay between AMPK/NFκB signaling and NLRP3 is a new therapeutic target in inflammation: emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury. Biomed. Pharmacother. 147, 112628 (2022)
D. Huang, F. Ju, L. Du, T. Liu, Y. Zuo, G.W. Abbott et al. Empagliflozin protects against pulmonary ischemia/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J. Pharmacol. Exp. Ther. 380, 230–241 (2022)
doi: 10.1124/jpet.121.000956
pubmed: 34893552
A.M. Kabel, R.S. Estfanous, M.M. Alrobaian. Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis. Respir. Physiol. Neurobiol. 273, 103316 (2020)
E.H. Baker, D.L. Baines. Airway glucose homeostasis: a new target in the prevention and treatment of pulmonary infection. Chest. 153, 507–514 (2018)
A. Åstrand, C. Wingren, A. Benjamin, J.S. Tregoning, J.P. Garnett, H. Groves et al. Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice. Br. J. Pharmacol. 174, 836–847 (2017)
doi: 10.1111/bph.13741
pubmed: 28192604
pmcid: 5386993
B. Chowdhury, A.Z. Luu, V.Z. Luu, M.G. Kabir, Y. Pan, H. Teoh et al. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem. Biophys. Res. Commun. 524, 50–56 (2020)
doi: 10.1016/j.bbrc.2020.01.015
pubmed: 31980166